Countries China
The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH,...
February 06, 2024 | News
It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously crafted to systematically evaluate the safety, tolerability, an...
February 06, 2024 | News
"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events a...
February 04, 2024 | News
Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and missi...
February 02, 2024 | News
WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...
January 31, 2024 | News
Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will le...
January 30, 2024 | News
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...
January 25, 2024 | News
Merck announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies Integrates company&rsq...
January 24, 2024 | News
Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...
January 24, 2024 | News
- Primary efficacy endpoints: NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD Activity Score) in ...
January 24, 2024 | News
The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target treatment,...
January 23, 2024 | News
The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been appr...
January 22, 2024 | News
The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Plat...
January 20, 2024 | News
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...
January 16, 2024 | News
Most Read
Bio Jobs
News
Editor Picks